Generic placeholder image

Recent Patents on Cardiovascular Drug Discovery

Editor-in-Chief

ISSN (Print): 2212-3962
ISSN (Online): 1574-8901

Latest Therapeutic Novelties and Patents in Pulmonary Hypertension

Author(s): Georgia F. Hardavella, Georgios S. Dionellis, Christina G. Kantza, Nikolaos G. Koulouris and Manos Alchanatis

Volume 6, Issue 1, 2011

Page: [55 - 60] Pages: 6

DOI: 10.2174/157489011794578491

Price: $65

Abstract

Recent advances in technology and novel pharmaceutical research findings have added new grounds in the fields of medical treatment and quality of life of patients diagnosed with pulmonary arterial hypertension (PAH). Collective assessment of new data is mandatory and useful for specialist medical doctors. This review aims to present the latest therapeutic developments of the last two years (2009-2010) in PAH. Moreover, recent patents (of the year 2010) regarding therapeutic novelties in PAH that expand treatment modalities, are hereby presented.

Keywords: Developments, patents, pulmonary arterial hypertension, therapeutic advances, therapeutic novelties, right heart catheterisation, PAH, phosphodiesterase-type 5, cGMP, sildenafil, PHIRST, right ventricular hypertrophy, eNOS, bosentan, sitaxsentan, ambrisentan, ambrisentan therapy, treprostinil, Rho kinase inhibitor, monocrotaline, azaindole-1, PASMCs, iloprost, XNT, right ventricular systolic, pressure, RVSP, Riociguat, epidermal growth factor, gefitinib, erlotinib, lapatinib, ACT-293987, selexipag, topiramate, tissue factor pathway inhibitor, tissue factor-mediated, downstream signaling pathway, calcitonin gene related peptide, CGRP, AMPK, AICAR, traditional chinese medicine, TCM


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy